Arrowhead Shoots For Obesity Bullseye Hoping To Pair Weight Loss With Muscle Preservation

Arrowhead, Altimmune & More: Obesity Drug Pipeline Update

Arrowhead Advances Two Obesity Drug Candidates to IND-Enabling Studies

After discontinuing its clinical-stage cardiovascular candidate, Arrowhead Pharmaceuticals has announced two promising obesity drug candidates are advancing to IND-enabling studies.

Preclinical data suggests the two candidates can reduce body weight and fat, making them promising additions to the obesity treatment pipeline.

Targeting Two Mechanisms for Enhanced Weight Loss

One of the candidates targets both GLP-1 and GIP, two mechanisms involved in regulating appetite and body weight.

Research suggests that targeting both mechanisms could lead to even more significant weight loss than targeting GLP-1 alone.

Altimmune's Pemvidutide Shows Promise in Phase 2 Obesity Trial

Altimmune has reported positive phase 2 data for its obesity drug candidate, pemvidutide.

Data from the trial suggests that pemvidutide may be best-in-class for weight loss and metabolic improvements.

Focus on Muscle Preservation

Other companies are exploring drugs that preserve or increase muscle mass during weight loss.

This is important because muscle loss is a common side effect of weight loss, which can lead to weakness and other health issues.

Ongoing Research in Obesity Drug Development

The obesity drug pipeline is rapidly expanding, with several companies developing novel therapies to combat this global health issue.

These advancements offer hope for more effective and comprehensive treatment options for individuals struggling with obesity.